Sökning: "Atrial Fibrillation: drug therapy"

Visar resultat 1 - 5 av 12 avhandlingar innehållade orden Atrial Fibrillation: drug therapy.

1. 1. Atrial fibrillation after cardiac surgery : an analysis of risk factors, mechanisms, and survival effects

   Författare :Giovanni Mariscalco; Bengt Åberg; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; atrial fibrillation; adult; cardiac surgery; coronary artery bypass grafting; valvular surgery; cardiopulmonary bypass; mortalilty; histology; catecholamines; embolism; Surgery; Kirurgi;

   Sammanfattning : Background: Despite the recent improvements in surgical techniques and postoperative patient care, atrial fibrillation (AF) remains the most frequent complication after cardiac surgery. Although postoperative AF is often regarded as a benign clinical condition, this arrhythmia has significant adverse effects on patient recovery and postoperative survival. LÄS MER

3. 2. Outcomes and safety of new techniques for pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation : A study based on randomised trials and registries

   Författare :David Mörtsell; Carina Blomström-Lundqvist; Stefan Lönnerholm; Isabel Deisenhofer; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; atrial fibrillation; antiarrhythmic drugs; ablation; cryoballoon; radiofrequency; pulmonary vein isolation; quality of life; arrhythmia monitoring; implantable cardiac monitor; atrial fibrillation burden; health economics; Cardiology; Kardiologi;

   Sammanfattning : Atrial fibrillation (AF) is a common disease with a high prevalence in the adult population. Treatment of AF encompasses antiarrhythmic drugs and catheter ablation to reduce symptoms. LÄS MER

4. 3. Risks and risk monitoring in sotalol therapy for atrial fibrillation

   Författare :Hanna Lenhoff; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :;

   Sammanfattning : Background: Atrial fibrillation (AF) stands as the most prevalent arrhythmia, significantly impacting both the prognosis and symptomatology of affected individuals. Healthcare expenditures associated with AF treatment and its related complications, in terms of morbidity and mortality, are substantial. LÄS MER

5. 4. Pharmacogenomics of Antihypertensive Treatment & Clinical Pharmacological Studies of Digoxin Treatment

   Författare :Pär Hallberg; Håkan Melhus; Ann-Christine Syvänen; Lars Lind; Jiguang Wang; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Molecular medicine; pharmacogenomics; irbesartan; atenolol; hypertension; digoxin; RIKS-HIA; atrial fibrillation; heart failure; Molekylärmedicin; Molecular medicine genetics and pathology ; Molekylär medicin genetik och patologi ;

   Sammanfattning : In Part I we found that the CYP2C9 genotype appears to influence the diastolic blood pressure response to the angiotensin II-receptor antagonist irbesartan in patients with hypertension and left ventricular hypertrophy. Those with the *1/*2 genotype (slower metabolism) responded better than those with the *1/*1 genotype (normal metabolism), likely due to a slower elimination of the drug. LÄS MER

7. 5. Warfarin treatment quality in stroke prevention

   Författare :Fredrik Björck; Anders Själander; Peter Svensson; Per Wester; Christine Kremer; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Anticoagulation; atrial fibrillation; complications; international normalized ratio INR variability; persistence; stroke; time in therapeutic range TTR ; treatment quality; warfarin; cardiovascular disease; hjärt- och kärlforskning;

   Sammanfattning : BackgroundIschemic stroke is a serious condition often associated to presence of atrial fibrillation (AF). Use of anticoagulants for AF patients greatly reduces the risk of stroke. Warfarin is the most commonly used anticoagulant in Sweden. The aim of this thesis was to study the impact of warfarin treatment quality in Swedish stroke prevention. LÄS MER